Compare Stocks: GNPX, KALA, FBLG, and LNAI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FBLG FibroBiologics	$1.43 -0.7%	$1.17	$0.62 ▼ $12.40	$9.59M	1.65	323,170 shs	117,073 shs
GNPX Genprex	$3.41 +3.0%	$5.53	$3.26 ▼ $1,210.00	$2.71M	-0.94	58,950 shs	26,793 shs
KALA KALA BIO	$0.52 +2.7%	$0.75	$0.49 ▼ $1,030.00	$9.82M	-2.28	743,942 shs	166,681 shs
LNAI Lunai Bioworks	$2.17 -0.9%	$2.40	$1.21 ▼ $15.36	$9.93M	0.35	31,542 shs	30,628 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FBLG FibroBiologics	-0.69%	-18.75%	+40.20%	+85.67%	-86.50%
GNPX Genprex	+3.02%	-0.58%	-23.71%	-73.41%	-98.86%
KALA KALA BIO	+2.74%	-6.31%	-42.69%	-85.55%	-99.94%
LNAI Lunai Bioworks	-0.91%	-16.86%	-3.56%	-42.59%	+216,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FBLG FibroBiologics	$1.43 -0.7%	$1.17	$0.62 ▼ $12.40	$9.59M	1.65	323,170 shs	117,073 shs
GNPX Genprex	$3.41 +3.0%	$5.53	$3.26 ▼ $1,210.00	$2.71M	-0.94	58,950 shs	26,793 shs
KALA KALA BIO	$0.52 +2.7%	$0.75	$0.49 ▼ $1,030.00	$9.82M	-2.28	743,942 shs	166,681 shs
LNAI Lunai Bioworks	$2.17 -0.9%	$2.40	$1.21 ▼ $15.36	$9.93M	0.35	31,542 shs	30,628 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FBLG FibroBiologics	-0.69%	-18.75%	+40.20%	+85.67%	-86.50%
GNPX Genprex	+3.02%	-0.58%	-23.71%	-73.41%	-98.86%
KALA KALA BIO	+2.74%	-6.31%	-42.69%	-85.55%	-99.94%
LNAI Lunai Bioworks	-0.91%	-16.86%	-3.56%	-42.59%	+216,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FBLG FibroBiologics	1.80	Reduce	$73.00	5,004.90% Upside
GNPX Genprex	1.00	Sell	N/A	N/A
KALA KALA BIO	1.80	Reduce	$75.00	14,278.83% Upside
LNAI Lunai Bioworks	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest GNPX, KALA, FBLG, and LNAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	FBLG FibroBiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
8/20/2026	FBLG FibroBiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
8/4/2026	FBLG FibroBiologics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00 ➝ $6.00
8/4/2026	FBLG FibroBiologics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Underperform
7/24/2026	FBLG FibroBiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/17/2026	GNPX Genprex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/8/2026	LNAI Lunai Bioworks	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/7/2026	FBLG FibroBiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
6/24/2026	KALA KALA BIO	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/17/2026	FBLG FibroBiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)

(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FBLG FibroBiologics	N/A	N/A	N/A	N/A	$1.85 per share	N/A
GNPX Genprex	N/A	N/A	N/A	N/A	$53.16 per share	N/A
KALA KALA BIO	N/A	N/A	N/A	N/A	$12.56 per share	N/A
LNAI Lunai Bioworks	N/A	N/A	N/A	N/A	($9.92) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FBLG FibroBiologics	-$18.65M	-$5.19	N/A	N/A	N/A	N/A	-536.78%	-225.12%	10/30/2026 (Estimated)
GNPX Genprex	-$16.23M	-$133.36	N/A	N/A	N/A	N/A	-163.12%	-128.98%	12/2/2026 (Estimated)
KALA KALA BIO	-$26.98M	-$31.96	N/A	N/A	N/A	N/A	-222.35%	-70.23%	11/10/2026 (Estimated)
LNAI Lunai Bioworks	-$178.01M	-$0.40	N/A	N/A	N/A	N/A	-1,243.45%	-1,617.76%	N/A

Latest GNPX, KALA, FBLG, and LNAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2026	Q2 2026	KALA KALA BIO	-$6.00	-$21.32	-$15.32	-$21.32	$25.00 million	N/A
8/14/2026	Q2 2026	GNPX Genprex	N/A	-$9.40	N/A	-$9.40	N/A	N/A
7/31/2026	Q2 2026	FBLG FibroBiologics	-$0.93	-$0.66	+$0.27	-$0.66	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FBLG FibroBiologics	N/A	N/A	N/A	N/A	N/A
GNPX Genprex	N/A	N/A	N/A	N/A	N/A
KALA KALA BIO	N/A	N/A	N/A	N/A	N/A
LNAI Lunai Bioworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FBLG FibroBiologics	N/A	2.64	2.64
GNPX Genprex	N/A	6.76	6.76
KALA KALA BIO	N/A	6.88	6.88
LNAI Lunai Bioworks	N/A	0.19	0.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FBLG FibroBiologics	N/A
GNPX Genprex	14.05%
KALA KALA BIO	24.61%
LNAI Lunai Bioworks	71.41%

Insider Ownership

Company	Insider Ownership
FBLG FibroBiologics	7.30%
GNPX Genprex	0.25%
KALA KALA BIO	2.24%
LNAI Lunai Bioworks	0.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FBLG FibroBiologics	10	6.66 million	6.17 million	N/A
GNPX Genprex	20	820,000	818,000	No Data
KALA KALA BIO	30	19.34 million	18.91 million	Not Optionable
LNAI Lunai Bioworks	20	4.53 million	4.51 million	N/A

GNPX, KALA, FBLG, and LNAI Headlines

Recent News About These Companies

Lunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AI

September 16 at 9:25 AM | prnewswire.com

Lunai Bioworks (NASDAQ: LNAI) Issues Correction to Press Release Regarding Second Amended Complaint

September 4, 2026 | prnewswire.com

Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit

August 27, 2026 | prnewswire.com

Lunai Bioworks Inc LNAI

August 13, 2026 | morningstar.comM

Lunai Bioworks Litigation Updates

August 6, 2026 | jdsupra.com

Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027

August 4, 2026 | prnewswire.com

Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit

August 4, 2026 | prnewswire.com

Why Did Lunai Bioworks Surge After Regaining Nasdaq Compliance?

June 17, 2026 | kalkinemedia.comK

Why Did LNAI Stock Soar Over 100% In Pre-Market Trading Today?

June 17, 2026 | finance.yahoo.com

Lunai Bioworks (LNAI) Stock Is Trending Overnight — Here's Why It Spiked Nearly 81% In After-Hours Session

June 17, 2026 | msn.com

LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS

June 17, 2026 | prnewswire.com

Lunai Bioworks (LNAI) Stock Is Trending Overnight â€” Here's Why It Spiked Nearly 81% In After-Hours Session

June 17, 2026 | feeds.benzinga.com

Lunai Bioworks & BrainStorm Therapeutics Launch Foundation-Funded Parkinson’s & Rare Epilepsy AI Discovery Collaboration

May 28, 2026 | tennessean.comT

Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration

May 28, 2026 | prnewswire.com

Federal Judge Orders Expedited Discovery to Identify 'John Doe' Defendants 'Naked' Short-Sellers of Lunai Common Stock

May 22, 2026 | prnewswire.com

Lunai Bioworks Announces 1-for-8 Reverse Stock Split

May 21, 2026 | theglobeandmail.com

LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT

May 20, 2026 | prnewswire.com

Lunai Bioworks: Fiscal Q3 Earnings Snapshot

May 15, 2026 | khou.comK

Dickinson Wright and Fox Rothschild Join Forces to File Lawsuit Against ‘John Doe’ ‘Naked’ Short-Sellers of Lunai Common Stock

May 12, 2026 | markets.businessinsider.com

Dickinson Wright and Fox Rothschild Join Forces to File Lawsuit Against ‘John Doe' ‘Naked' Short-Sellers of Lunai Common Stock

May 11, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX, KALA, FBLG, and LNAI Company Descriptions

FibroBiologics NASDAQ:FBLG

$1.43 -0.01 (-0.69%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$1.49 +0.06 (+4.13%)

As of 07:00 AM Eastern

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

Genprex NASDAQ:GNPX

$3.41 +0.10 (+3.02%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$3.40 -0.01 (-0.29%)

As of 06:45 AM Eastern

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

KALA BIO NASDAQ:KALA

$0.52 +0.01 (+2.74%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$0.56 +0.04 (+8.13%)

As of 06:56 AM Eastern

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Lunai Bioworks NASDAQ:LNAI

$2.17 -0.02 (-0.91%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$2.24 +0.08 (+3.46%)

As of 04:10 AM Eastern

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GNPX, KALA, FBLG, and LNAI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GNPX, KALA, FBLG, and LNAI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GNPX, KALA, FBLG, and LNAI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX, KALA, FBLG, and LNAI Company Descriptions

FibroBiologics NASDAQ:FBLG

Genprex NASDAQ:GNPX

KALA BIO NASDAQ:KALA

Lunai Bioworks NASDAQ:LNAI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GNPX, KALA, FBLG, and LNAI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GNPX, KALA, FBLG, and LNAI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GNPX, KALA, FBLG, and LNAI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX, KALA, FBLG, and LNAI Company Descriptions

FibroBiologics NASDAQ:FBLG

Genprex NASDAQ:GNPX

KALA BIO NASDAQ:KALA

Lunai Bioworks NASDAQ:LNAI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools